{content}

Study list

PostCoV2OSA

Portugal
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

PRECISE

Austria
|
2022-2025
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Primary care
  • SARS-CoV-2
  • Post COVID-19 condition

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Reuken

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

EuCARE-HOSPITALISED

Sweden Italy Poland Portugal Germany Lithuania United Kingdom Kenya Brazil Mexico
|
2022
  • Adults (18-64 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Blood sample
  • Nasopharyngeal swab
  • Urine sample

Mikulska

Italy
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

SIPCOV

Norway
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

Schols

Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

Mazzitelli 2

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Monoclonal antibodies
  • Immunomodulator
  • Antineoplastic agent
  • Imatinib
  • Infliximab

Paraskevis

Greece
|
2022-2022
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Mondì

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Pregnant women
  • Hospital
  • Outpatient clinic
  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Sexually transmitted infection

Petersen

Faroe Islands
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition

InsCOVID

Spain
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Rehabilitation

Mazzitelli

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

E-APLICOV-PC

Spain
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Antivirals
  • Plitidepsin

Braunstahl

The Netherlands
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition
  • Non pharmacological intervention
  • Dietary
  • Lifestyle

LOCOMOTION

United Kingdom
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • Primary care
  • Telemedicine
  • SARS-CoV-2
  • Post COVID-19 condition

SENSING-AI

Spain
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post COVID-19 condition

De Vito

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

SYNPOCov

France
|
2022-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post COVID-19 condition

Del Borgo

Italy
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

Zeyen

Germany
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox

Basoulis

Greece
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir